|
|
News Breaks | | | | October 15, 2012 | | 05:41 EDT |  | INO | Inovio Pharma animal health subsidiary's GHRH treatment approved in New Zealand
Inovio Pharmaceuticals announced that its majority-owned subsidiary, VGX Animal Health, has received approval to market LifeTide SW 5.0, the world's first approved growth hormone releasing hormone, or GHRH, therapy for food animals, in New Zealand. LifeTide is a once-in-a-lifetime treatment for female pigs (sows) that has demonstrated significant decreases in perinatal mortality of piglets from treated sows compared to untreated sows. The treatment, which increases the number of weaned piglets and results in greater overall meat production, was previously approved in Australia. | |
|
News For INO From The Last 14 Days Check below for free stories on INO the last two weeks. |
|
|
| May 14, 2013 | | 09:18 EDT | | INO | Inovio announces positive results from preclinical study of SynCon DNA vaccine
Inovio announced that in a preclinical study of Inovio's SynCon DNA vaccine against Ebola and Marburg filoviruses, labeled "Category A" bioterrorism agents by the U.S. government, the vaccine induced strong and broad immune responses and demonstrated 100% protection against death following a challenge with multiple variants of the pathogen in two animal models. | | | May 10, 2013 | | 16:42 EDT |  | INO | Inovio reports Q1 EPS (6c), consensus (4c)
 Subscribe for More Information | |
|
|
|
|
|
|
